Xencor, Inc. (XNCR)
NASDAQ: XNCR · Real-Time Price · USD
11.23
-0.28 (-2.43%)
At close: Mar 28, 2025, 4:00 PM
10.81
-0.42 (-3.78%)
After-hours: Mar 28, 2025, 4:27 PM EDT
Xencor Revenue
In the year 2024, Xencor had annual revenue of $110.49M, down -36.72%. Xencor had revenue of $70.02M in the quarter ending December 31, 2024, with 37.38% growth.
Revenue (ttm)
$110.49M
Revenue Growth
-36.72%
P/S Ratio
6.78
Revenue / Employee
$441,972
Employees
250
Market Cap
791.29M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 110.49M | -64.12M | -36.72% |
Dec 31, 2023 | 174.62M | 10.04M | 6.10% |
Dec 31, 2022 | 164.58M | -110.53M | -40.18% |
Dec 31, 2021 | 275.11M | 152.42M | 124.23% |
Dec 31, 2020 | 122.69M | -34.01M | -21.70% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionXNCR News
- 15 days ago - Xencor Appoints Todd Simpson to Board of Directors - Business Wire
- 4 weeks ago - Xencor Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 5 weeks ago - 20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset' - Market Watch
- 4 months ago - Xencor to Participate at Upcoming Investor Conferences - Business Wire
- 4 months ago - Xencor: Plamotamab NHL Data Leads To RA Program Advancement - Seeking Alpha
- 5 months ago - Xencor Reports Third Quarter 2024 Financial Results - Business Wire
- 5 months ago - Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease - Business Wire
- 6 months ago - Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases - Business Wire